Caricamento...

Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Petrich, Adam, Nabhan, Chadi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2016
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950458/
https://ncbi.nlm.nih.gov/pubmed/27118119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1160082
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !